United Therapeutics Corporation reports results for the quarter ended September 30 - Earnings Summary

• United Therapeutics Corporation reported quarterly adjusted earnings of $5.71​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of $7.16. The mean expectation of fourteen analysts for the quarter was for earnings of $6.42 per share. Wall Street expected results to range from $4.40 to $7.63 per share.

• Revenue rose 4.1% to $832.50 million from a year ago; analysts expected $781.22 million.

• United Therapeutics Corporation's reported EPS for the quarter was $5.71​.

• The company reported quarterly net income of $258.6 million.

• United Therapeutics Corporation shares had risen by 11.0% this quarter and gained 23.4% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 0.4% in the last three months.​

• In the last 30 days, three analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for United Therapeutics Corporation is $690.00, about 12.9% above its last closing price of $601.32

This summary was machine generated from LSEG data November 4 at 02:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)